Targeted drug shrinks tumors in 3 out of 4 patients with advanced breast cancer
- The drug extended median time without progression to 16.4 months.
- Tumours shrank in 75.5% of patients treated with it.
- Serious side effects were more common than with chemotherapy.
A phase three trial found that trastuzumab rezetecan delayed tumour growth more than standard chemotherapy in women with advanced breast cancer whose tumours have low levels of HER2. The findings suggest the drug could offer patients longer before their cancer worsens, including across hormone receptor-positive and hormone receptor-negative…